Prevalence and impact of endocrine disorders in advanced metastatic cancer patients undergoing cancer-directed therapy: A prospective observational study.
Gaurav KarnaAmit SehrawatSaurabh KarnaRavi KantDeepak SundriyalSummi KarnDipesh JhaPublished in: Cancer reports (Hoboken, N.J.) (2024)
Our study highlights the importance of considering endocrine disorders in advanced metastatic cancer patients undergoing therapy. The prevalence of diabetes and thyroid dysfunction increased during cancer-directed therapy, particularly in females. Careful monitoring and timely intervention are essential to improve the quality of life for these patients. Further research is warranted to explore the long-term effects of cancer-directed therapy on endocrine health and develop tailored management strategies for this vulnerable population.
Keyphrases
- papillary thyroid
- patients undergoing
- squamous cell
- squamous cell carcinoma
- small cell lung cancer
- randomized controlled trial
- healthcare
- cardiovascular disease
- public health
- end stage renal disease
- stem cells
- chronic kidney disease
- metabolic syndrome
- newly diagnosed
- ejection fraction
- childhood cancer
- young adults
- bone marrow
- mesenchymal stem cells
- risk assessment
- smoking cessation
- cell therapy